FAP and neoplasm: Continuing the clinical assessment of the radiolabeled FAP-based inhibitors, FAPI-21 and FAPI-46—the other two outstanding FAPI derivatives that developed in an attempt to improve FAPI-04 performance—indeed, showed superior tumor accumulation and tumor-to-background ratios over FAPI-04 [110].